GlycoVaxyn AG has appointed Philippe Dro as chief executive officer and a member of the supervisory board.
The privately-held Swiss company develops and produces immunogenic glycoproteins for use in vaccines in a simplified process that significantly reduces costs compared to traditional vaccine technology. It is currently conducting preclinical tests on three bioconjugate vaccines against severe bacterial infections.
Dr Dro was previously chairman and CEO of Endoart SA, a medtech company which was sold to Allergan Inc of the US.
Founded in 2004 as a spin-out company from the Swiss Federal Institute of Technology, GlycoVaxyn has been funded by Sofinnova Partners and Index Ventures.
Source:
GlycoVaxyn press release, 20 May 2008
Copyright 2008 Evernow Publishing Ltd